Pfizer announced that the FDA has approved Velsipity, an oral, once-daily, selective sphingosine-1-phosphate, or S1P receptor modulator for adults with moderately to severely active ulcerative colitis, or UC. The approved recommended dose for Velsipity is 2 mg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE: